Legend Biotech (LEGN) to Release Earnings on Monday

Legend Biotech (NASDAQ:LEGN) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Legend Biotech to post earnings of ($0.18) per share and revenue of $237.49 million for the quarter.

Legend Biotech (NASDAQ:LEGN) last released its earnings results on Tuesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.33. The company had revenue of $195.05 million during the quarter, compared to analyst estimates of $190.83 million. Legend Biotech had a negative return on equity of 21.19% and a negative net margin of 29.95%. The company’s revenue for the quarter was up 107.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.16) earnings per share. On average, analysts expect Legend Biotech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Legend Biotech Price Performance

LEGN opened at $37.00 on Friday. The stock has a fifty day moving average of $37.25 and a 200-day moving average of $35.18. The firm has a market capitalization of $6.80 billion, a P/E ratio of -62.71 and a beta of 0.26. Legend Biotech has a 12-month low of $27.34 and a 12-month high of $59.62. The company has a quick ratio of 5.07, a current ratio of 5.20 and a debt-to-equity ratio of 0.30.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on LEGN. Morgan Stanley restated an “overweight” rating and issued a $81.00 target price (up previously from $80.00) on shares of Legend Biotech in a report on Thursday, July 10th. Cantor Fitzgerald upgraded Legend Biotech to a “strong-buy” rating in a report on Monday, August 4th. Royal Bank Of Canada restated an “outperform” rating and issued a $84.00 target price on shares of Legend Biotech in a report on Tuesday, April 22nd. Truist Financial cut their price objective on Legend Biotech from $88.00 to $71.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. Finally, Johnson Rice reiterated a “buy” rating on shares of Legend Biotech in a report on Thursday, July 17th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $73.33.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).